DNTH Dianthus Therapeutics, Inc. /DE/ Insider Trading

CFO Ryan Savitz sells 31,249 shares for $3,157,150.86 via scheduled 10b5-1 plan; retains 68,751 options.

Ryan Savitz, EVP, CFO & CBO, executed 3 separate sales on 2026-07-09 totaling 31,249 shares for $3,157,150.86 at a blended average price of $101.03, reducing his non-derivative holdings to zero while retaining 68,751 shares via stock options. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-30, meaning execution is scheduled rather than discretionary. The stock currently trades at $98.64, a 3.6% discount from its 52-week high of $102.33, and has risen 20.2% over the past 30 days and 3.9% over 90 days. Context matters: DNTH reported quarterly revenue of $396,000.00 and a net loss of $-40,834,000.00, with annual revenue declining 67.4% year-over-year, placing the company in a distressed financial position despite its $5.4B market cap. His prior sales at this ticker (5 trades between March and April 2026) showed 30-day returns ranging from -3.5% to +11.3%, with his cross-ticker track record displaying an average 90-day return of +18.7% following sales.

SVP/General Counsel Adam M Veness sells 30,000 shares for $2.4M via scheduled 10b5-1 plan at DNTH

Adam M Veness, SVP General Counsel and Secretary, executed 2 separate sales totaling 30,000 shares for $2,423,958.16 on 2026-06-17 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-18—a scheduled, non-discretionary transaction. The company faces significant headwinds: Revenue declined to $396,000.00 in the latest quarter, annual revenue growth was -67.4%, and net income was negative at $-40,834,000.00 over the most recent full fiscal year. Veness retains 80,000 shares in stock options (Table II derivative holdings), preserving meaningful exposure to the company. The scheduled nature of this sale removes any inference about timing or conviction; however, the magnitude of the revenue contraction and persistent losses underscore the operational challenges facing Dianthus Therapeutics.

EVP R&D Simrat Randhawa sells 26,530 shares ($2.4M) via 10b5-1 plan; retains 4,000 shares + 209,076 in derivatives.

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, executed three separate sales totaling 26,530 shares for $2,404,076.95 at a blended average price of $90.62 on 2026-06-01. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sales were scheduled rather than discretionary. The insider's non-derivative holdings fall from 30,530 shares to 4,000 shares, representing a reduction of 86.9%, while substantial derivative holdings (209,076 shares across four stock options) remain post-transaction. At the current price of $81.57, the stock trades 15.5% below its 52-week high of $96.50, having declined 6.7% over the past 30 days despite a 31.5% gain over the past 90 days. The company reported revenue of $396,000.00 in the latest quarter, a net loss of $40,834,000.00, and annual revenue growth of -67.4%, with no profitability over its most recent full fiscal year. Prior sales by this insider at DNTH over the last eight months have consistently produced positive subsequent returns: a +10.2% 30-day return on the 2026-03-12 sale and multi-month returns ranging from +9.8% to +39.4% on five trades between November 2025 and March 2026. The scheduled nature of this divestment under a 10b5-1 plan precludes timing-based inference, but the context—significant share reduction paired with retained derivative exposure, severe revenue contraction, and ongoing losses—warrants attention to operational fundamentals.

CFO Ryan Savitz sold 8,224 shares of DNTH at $89.84, fully exiting position via pre-arranged 10b5-1 plan adopted 2025-12-30.

Savitz, serving as EVP, CFO & CBO, sold 8,224 shares for a total value of $738,844.16, reducing his holdings from 8,224 shares to 0 shares. This represents a complete exit from his equity stake in Dianthus Therapeutics. The sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-30, meaning the transaction followed a scheduled formula established in advance rather than a discretionary decision at the time of sale. Complete position liquidations by senior financial officers warrant disclosure review, though the plan-based nature indicates the timing and volume were predetermined rather than reactive to current conditions.

CFO Ryan Savitz sold all 114,367 shares via 8 separate transactions on 2026-03-31 for $9,492,595.50 under 10b5-1 plan

Ryan Savitz, EVP, CFO & CBO, executed 8 separate sales totaling 114,367 shares for $9,492,595.50 on 2026-03-31 through a pre-arranged 10b5-1 trading plan adopted on 2025-12-30. The complete liquidation—from 114,367 shares to 0 shares post-transaction—represents a -100.0% reduction in his holdings at the company. Transaction prices ranged from $78.33 to $85.54 across the sales, with a blended average price of $83.00. Because this activity is part of a scheduled 10b5-1 plan rather than discretionary trading, the transaction reflects a predetermined execution rather than a market-responsive decision by the CFO.

Director Paula Soteropoulos sells all 27,594 DNTH shares at $78.05 under 10b5-1 plan; position reduced to zero.

Paula Soteropoulos, a Director, executed a complete exit from her Dianthus Therapeutics position by selling 27,594 shares at $78.05 on 2026-03-24, reducing her holdings to 0 shares from 27,594 shares pre-transaction. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-23, meaning the transaction was scheduled rather than discretionary. The total value of this disposition was $2,153,711.70, representing a 100% reduction in her stated holdings and a complete elimination of director-level equity exposure to the company.

CEO Garcia Marino sells 122.9K shares for $10.0M under 10b5-1 plan; holds zero post-transaction

CEO and President Garcia Marino executed 5 separate sales totaling 122,918 shares for $10,016,380.63 at a blended average price of $81.49 on 2026-03-12, reducing his holdings from 122.9K shares to zero. This complete liquidation of his equity stake represents a material change in insider ownership structure. The transaction is scheduled under a 10b5-1 trading plan adopted on 2025-11-17, meaning execution timing was predetermined rather than discretionary. Complete CEO equity exit warrants investor attention regarding alignment between management and shareholder interests going forward.

CAO Edward Carr sold all 43,682 shares for $3,559,494.57 on 2026-03-12 via scheduled 10b5-1 plan

Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, completed a liquidation of his entire equity stake through 5 separate sales totaling 43,682 shares for $3,559,494.57. The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-11, meaning the sales were scheduled rather than discretionary. Post-transaction holdings stand at zero shares. The multi-tranche execution at prices ranging from $80.71 to $85.53 reflects a systematic disposition plan, not a concentrated single transaction.

EVP R&D Randhawa sold entire 33,830-share stake at $81.48 under 10b5-1 plan; zero shares remain

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, executed a complete exit of his equity holdings, selling 33,830 shares for $2,756,468.40 on 2026-03-12. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sale was scheduled in advance rather than discretionary. The elimination of his entire position eliminates an insider's ongoing financial alignment with the company's performance; however, the pre-arranged nature of the transaction precludes attribution to recent business developments or near-term outlook shifts. The post-transaction holding of 0 shares represents a complete dissolution of directly held equity exposure by a senior R&D executive.

CFO Savitz Ryan sold 20,000 shares of DNTH at $45.18 (total $903,600) via pre-arranged 10b5-1 plan; reduced to zero holdings.

Savitz Ryan, serving as CFO & CBO, executed a complete liquidation of his 20,000 shares (-100.0% of pre-transaction holdings) under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31. The transaction was scheduled, not discretionary, meaning it was locked in months in advance and reflects no real-time judgment about current stock levels. The sale reduced his post-transaction holdings to 0 shares, eliminating his direct equity stake in the company. While complete insider liquidations warrant attention for potential signaling, the 10b5-1 plan structure removes timing-based inference—the sale date and price were predetermined and legally divorced from current sentiment or knowledge.